Fig. 3From: Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanomaKaplan-Meier curves for PFS during VEM1-IPI (a) and OS (b). The median PFS was 4.5 months (95 % CI: 4.17–6.57). At a median follow-up of 15.3 months, the median OS was 18.5 months (95 % CI: 11.96–not evaluable)Back to article page